

Cryoport, Inc. (CYRX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001124524

Cryoport, Inc. CYRX; healthcare	
Grade	C/D A B C D E on the C/D boundary of 371 graded peers percentile 59.2; sampling error 2.5 points; lower is stronger
Rank	220 of 371
Profitability	D percentile 62.7
Solvency	B percentile 35.3
Growth and financing	C percentile 55.1
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$765.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	late filer
Inputs computable	9 of 14
Graded from	filings received through Mar 5, 2026 218 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$16.91 2026-10-08; market equity \$856.7M
Price used in grade	None



C/D, the tortoise
on the C/D boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Feb 21, 2025, C from Mar 21, 2025, D from Mar 21, 2026, C/D from Aug 6, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy ("CGT") market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and

immunotherapies.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 62.7						
Gross profitability		10.9%	32.2%	74.9	372	2025-12-31
Return on invested capital		not computable	9.3%			a prior annual debt, equity, and cash observation is required
Accruals ratio		11.8%	(6.6%)	92.2	811	2025-12-31
Gross margin stability, five years		1.3 pts	2.8 pts	21.1	243	2025-12-31
Solvency, sleeve percentile 35.3						
Twelve-month failure probability		0.02%	0.07%	4.0	248	2026-06-30
Altman Z double-prime		0.96	(0.31)	32.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.17x	2.96x	68.9	839	2025-12-31
Growth and financing, sleeve percentile 55.1						
Revenue growth, three-year compound		(9.4%)	10.0%	84.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(9.7%)	2.1%	68.8	704	2025-12-31
Net share issuance, one year		(0.1%)	2.5%	11.5	634	2026-02-27


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
215	electroCore, Inc. (ECOR)	57.8	C/D	
216	Rocket Pharmaceuticals, Inc. (RCKT)	58.1	C/D	degenerate inputs
217	Prestige Consumer Healthcare Inc. (PBH)	58.4	C/D	
218	Becton Dickinson & Co. (BDX)	58.6	C/D	
219	Option Care Health, Inc. (OPCH)	58.9	C/D	
220	Cryoport, Inc. (CYRX) <	59.2	C/D	late filer
221	GeneDx Holdings Corp. (WGS)	59.5	C/D	fortress balance sheet
222	Trulieve Cannabis Corp. (TRLV)	59.7	C/D	fortress balance sheet
223	Labcorp Holdings Inc. (LH)	60.0	C/D	
224	Perspective Therapeutics, Inc. (CATX)	60.3	C/D	dilution, fortress balance sheet
225	ARS Pharmaceuticals, Inc. (SPRY)	60.5	C/D	short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	68.8%	8.0%	83
Distance from 52-week high	(6.8%)	(31.4%)	91
EBIT to enterprise value	(6.3%)	(1.5%)	38
Free cash flow yield	(2.9%)	(1.0%)	45
Book value to price	0.57	0.28	73
Sales to price	0.21	0.31	39
Composite equity issuance, five years	10.5%	20.3%	40
Relative strength against the sector, log excess return	0.31	(0.14)	83

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$269.3M

Operating cash flow, four quarters	\$8.0M
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$9.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$83.1M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
2	assets	us-gaap:Assets	\$765.0M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
3	operating income	us-gaap:OperatingIncomeLoss	-\$6.3M	2013-03-31	2014-06-25	10-K	0001144204-14-039508
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	\$6.4M	2013-03-31	2014-06-25	10-K	0001144204-14-039508
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1,600	2013-03-31	2014-06-25	10-K	0001144204-14-039508
6	total debt	us-gaap:LongTermDebt	\$1.3M	2013-03-31	2013-06-25	10-K	0001144204-13-036463
7	book equity	us-gaap:StockholdersEquity	-\$2.1M	2013-03-31	2015-05-19	10-K	0001144204-15-032332
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$563,104	2013-03-31	2015-05-19	10-K	0001144204-15-032332
9	net income	us-gaap:NetIncomeLoss	\$78.3M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$8.6M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
11	assets	us-gaap:Assets	\$703.5M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$176.2M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
13	gross profit	us-gaap:GrossProfit	\$69.7M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$156.8M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
15	gross profit	us-gaap:GrossProfit	\$75.3M	2023-12-31	2026-03-05	10-K	0001104659-26-024180
16	revenue	us-gaap:Revenues	\$168.7M	2023-12-31	2026-03-05	10-K	0001104659-26-024180
17	gross profit	us-gaap:GrossProfit	\$103.9M	2022-12-31	2025-03-07	10-K	0001558370-25-002509
18	revenue	us-gaap:Revenues	\$237.3M	2022-12-31	2025-03-07	10-K	0001558370-25-002509
19	gross profit	us-gaap:GrossProfit	\$96.6M	2021-12-31	2024-03-13	10-K	0001558370-24-003128
20	revenue	us-gaap:Revenues	\$222.6M	2021-12-31	2024-03-13	10-K	0001558370-24-003128
21	current assets	us-gaap:AssetsCurrent	\$476.2M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
22	current liabilities	us-gaap:LiabilitiesCurrent	\$219.0M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$688.9M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
24	operating income	us-gaap:OperatingIncomeLoss	-\$36.8M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
25	book equity	us-gaap:StockholdersEquity	\$502.6M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
26	liabilities	us-gaap:Liabilities	\$262.4M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
27	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$393,959	2013-03-31	2014-06-25	10-K	0001144204-14-039508
28	operating income	us-gaap:OperatingIncomeLoss	-\$100.5M	2023-12-31	2026-03-05	10-K	0001104659-26-024180
29	interest expense	us-gaap:InterestExpense	\$5.5M	2023-12-31	2024-03-13	10-K	0001558370-24-003128
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$16.4M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$16.3M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$17.3M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$757,000	2023-12-31	2026-03-05	10-K	0001104659-26-024180
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$38.8M	2023-12-31	2026-03-05	10-K	0001104659-26-024180
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$1.9M	2022-12-31	2025-03-07	10-K	0001558370-25-002509
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$22.1M	2022-12-31	2025-03-07	10-K	0001558370-25-002509
37	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$27.7M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
38	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$10.2M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
39	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.8M	2025-12-31	2026-03-05	10-K	0001104659-26-024180
40	current assets	us-gaap:AssetsCurrent	\$341.6M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
41	current liabilities	us-gaap:LiabilitiesCurrent	\$64.6M	2024-12-31	2026-03-05	10-K	0001104659-26-024180
42	assets	us-gaap:Assets	\$957.7M	2023-12-31	2025-03-07	10-K	0001558370-25-002509
43	assets	us-gaap:Assets	\$1.0B	2022-12-31	2024-03-13	10-K	0001558370-24-003128
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,856,135	2026-02-27	2026-03-05	10-K	0001104659-26-024180
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,910,391	2025-02-28	2025-03-07	10-K	0001558370-25-002509